Within antibody engineering and therapeutics, the industry is working on a number of different modalities, including monoclonal antibodies (mAbs), protein therapeutics, bispecifics, immuno-oncology checkpoints, antibody-drug conjugates (ADCs) and CAR-T/cellular therapies. At the same time, work on these modalities is increasingly exploring new non-cancer targets.
Over the following pages, we explore these novel antibody modalities, including lessons and strategies within the world of conjugation, the search for perfection in bispecifics, a snapshot of the current scope of the industry, and how therapeutic development is being affected by the rapid spread of COVID-19.
